We’re on a Mission to Improve the Human Condition

Combining cutting-edge data science and human genetics, we’re creating precision medicines to fight debilitating diseases.

Learn About Our Company
IT’S ALL POSSIBLE.

We leverage an innovative drug discovery model to accelerate the identification of novel molecular targets and create effective precision medicine treatments with more efficiency than ever before.

We’re Rewriting the Narrative
to Change the Future

Neuron23 Envisions a World Where Every Disease has a Treatment Through Breakthrough Science, Powered by Personalized Medicine

Our Science

Meet the Heart of Neuron23

We're a diverse team with proven success in both science and business, driven by one common goal: enhancing and improving the lives of the patients we serve. Compassion is at our core, and we're on a never-ending mission to create the type of breakthroughs that can propel the world forward.

Meet Our Team

Latest News

  • NEWS /

    Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug

    Collaboration combines leading expertise of Neuron23 in drug discovery, data science, and machine learning with QIAGEN’s long-standing experience in companion diagnostic development SOUTH SAN FRANCISCO, Calif. and GERMANTOWN, Md. and HILDEN, Germany, Sept. 14, 2022 /PRNewswire/ — Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological […]

    Read More
  • NEWS /

    Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer

    Longtime clinical development leader will help advance pipeline of precision medicines for genetically defined neurological and immunological diseases, with initial focus on Parkinson’s disease SOUTH SAN FRANCISCO, Calif., April 12, 2022 – Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment […]

    Read More
  • NEWS /

    Neuron23 Closes $100 Million Series C Financing Round, Nominates Clinical Candidate for Parkinson’s Disease

    SoftBank Vision Fund 2 leads round with participation from all existing investors . Company expects to bring LRRK2 candidate into the clinic for Parkinson’s disease by end of 2022. Valentin Barsan, M.D., and Jim Scopa join Neuron23 board of directors

    Read More
See All News

Be in the Room When History is Made

We're looking for team members with an insatiable hunger for creating change and the talent to make it happen — those ready to meet us where we are and excited to help take us where we want to go.

Current Opportunities